Albumin, Cynomolgus Monkey [70024-90-7]
16-16-011202-CM
Protein IDA2V9Z4
Product group Proteins / Signaling Molecules
Overview
- SupplierAthens Research
- Product NameAlbumin, Cynomolgus Monkey [70024-90-7]
- Delivery Days Customer9
- Applications SupplierCell Culture Media, In Vitro Diagnostic, Calibrators, Control, Antisera Production, Protein Chemistry, Therapeutics Research
- CAS Number70024-90-7
- CertificationResearch Use Only
- Gene ID102130757
- Target nameALB
- Target descriptionalbumin
- Target synonymsalbumin, Qlv-U377A-G8, Serum albumin
- Protein IDA2V9Z4
- Protein NameAlbumin
- Scientific DescriptionAlbumin constitutes 60% of plasma proteins and exhibits exceptional structural stability due to its 17 disulfide bonds and conserved N-glycosylation. Beyond maintaining 80% of plasma oncotic pressure to prevent vascular fluid leakage, albumin binds and transports hydrophobic ligands-including fatty acids, steroids, thyroid hormones, calcium ions, and over 90% of circulating drugs-via its dynamic binding pockets. Its free Cys34 residue confers antioxidant properties by scavenging reactive oxygen species. Hypoalbuminemia (less then3.5 g/dL) arises from hepatic dysfunction (cirrhosis, hepatitis), renal protein loss (nephrotic syndrome), chronic inflammation, or malnutrition. Clinically, it manifests as edema, ascites, and impaired drug efficacy due to reduced ligand binding. Conversely, glycated albumin contributes to diabetic complications by promoting vascular endothelial dysfunction3. Therapeutically, human serum albumin (HSA) has been administered since 1941 for hypovolemia and burns, with modern 5% and 25% solutions managing ARDS and cardiopulmonary bypass. With a 19-day circulatory half-life, albumin stabilizes cell culture media.
- Shelf life instructionmore then 1 year
- SourceCynomolgus Monkey plasma was obtained from healthy animals of US origin and under the care of a registered veterinarian. Prepared from donor monkeys that have been individually tested for B-Virus (Herpes Virus Simiae) and found to be negative.
- Storage Instruction≤ -20°C
- UNSPSC12352202
References
- Liu, H., et al., (2021), 'An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade', International Immunopharmacology 101: pp 108307Read this paper
- Tamburini, P., et al., (2024), 'Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration', MABS, 16(1): pp 2415060Read this paper
- Jindal, S., et al., (2024), 'Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration', Molecular Immunology 165: pp 29–41Read this paper